Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $20.2200 (7.44%) ($18.2200 - $20.6800) on Mon. May. 11, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.88% (three month average) | RSI | 77 | Latest Price | $20.2200(7.44%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 9% a day on average for past five trading days. | Weekly Trend | TGTX advances 26.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(62%) ARKG(57%) ARKK(54%) IBB(54%) IWO(53%) | Factors Impacting TGTX price | TGTX will decline at least -4.44% in a week (0% probabilities). VIXM(-33%) VXX(-32%) UUP(-15%) DRIV(-2%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.44% (StdDev 8.88%) | Hourly BBV | 0 () | Intraday Trend | 9.3% | | | |
|
5 Day Moving Average | $18.71(8.07%) | 10 Day Moving Average | $15.5(30.45%) | 20 Day Moving Average | $13.78(46.73%) | To recent high | 0% | To recent low | 183.2% | Market Cap | $2.561b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |